New Treatment for the Reduction of LDL: Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosingand provides effective and sustained LDL-C reduction.
High levels of blood cholesterol, particularly low-density lipoproteins (LDL-C), are known to be a significant contributor to cardiovascular disease. In 2019, the FDA reviewed the application for inclisiran in treating primary hyperlipidemia in adults who have elevated LDL-C while on a maximally tolerated dose of statin therapy. Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosing (twice per year) and provides effective and sustained LDL-C reduction in conjunction along with statins. Its prolonged effect may help alleviate medication non-compliance, one of the leading causes of failure to lower cholesterol levels. Inclisiran was FDA approved in December 2021 and is widely considered a game-changer for heart disease patients.
Latest from Today's Medical Developments
- Building, maintaining the Navy’s next generation of maritime platforms
- Pioneering battery-free cardiac implants
- KBC Tools & Machinery marks its 60th anniversary, Founder’s Day
- Address the challenges of machining high-temperature aerospace components
- Elevate your manufacturing operations with April’s Manufacturing Lunch + Learn
- AdvaMed statement on tariff announcement
- Collets – Not all are created equal
- ENGEL expands production capacities in the Americas; new plant opened in Mexico
